Research Paper Volume 12, Issue 21 pp 21904—21922

Figure 4. LINC00968 inhibits tumor development by regulating the miR-21-5p/SMAD7 axis. (A) FISH detection of subcellular localization of LINC00968 in A549 and H1299 cells. (B) The miRNACancerMAP datasets suggested that there was a significant positive correlation between LINC00968 and SMAD7. (C) The miRNAs negatively related to LINC00968 and SMAD7 most frequently were summarized by miRNACancerMAP. (D) Correlation between LINC00968 and the top 12 most frequent miRNAs. (E) Correlation between SMAD7 and the top 12 most frequent miRNAs. (F) qRT-PCR quantification of LINC00968. LINC00968 was more enriched in the cells treated with the Ago2 antibody compared with those treated with the IgG negative control antibody. (G) The complementary sites of LINC00968, miR-21-5p, and SMAD7. (H) The expression of miR-21-5p was decreased and increased in LINC00968 overexpressing and knockdown LUAD cells, respectively. (I) LINC00968 expression was decreased in the miR-21-5p mimics group and increased in the miR-21-5p inhibitor group. (J) H1299 and A549 cells co-transfected with a miR-21-5p mimic or negative control (NC) and luciferase vectors containing either wild type (LINC00968-WT) or mutated (LINC00968-mut) miR-21-5p-binding sites. The luciferase activity was measured after 48 h. (K) and (L) SMAD7 and YAP1 protein expression following LINC00968, SMAD7 and/or miR-21-5p modulation in A549 and H1299 cells. *P<0.05, **P<0.01, ***P<0.001.